RSH.AX Respiri Limited ASX 13 Mar 2026: Oversold bounce offers A$0.07 target

RSH.AX stock finished the ASX session at A$0.033 on 13 Mar 2026 after trading between A$0.03 and A$0.033, leaving the share price technically oversold. Volume was 579,396 shares, below the 50-day trend, which can produce a short-term bounce. Investors should weigh the bounce trade against weak fundamentals, thin liquidity and past YTD decline of 58.23% when sizing positions.

Market snapshot for RSH.AX stock and sector context

Respiri Limited (RSH.AX) is a Melbourne-based healthcare devices and e-health SaaS company trading on the ASX. The stock closed at A$0.033 on 13 Mar 2026 with a market capitalisation of A$51,984,240.00 and shares outstanding 1,575,280,000.00. The Healthcare sector on the ASX shows a muted trend with 1Y performance near 1.96%, leaving small-cap medical device names vulnerable to swings in risk appetite. source

Why the oversold bounce trade is valid for RSH.AX stock

Price action shows a steep decline YTD of 58.23%, with the stock sitting near its short-term support at A$0.03 and year low A$0.021. Reduced selling intensity and a relative volume of 0.67 suggest selling has paused. In small-cap healthcare names, short-term technical rebounds commonly produce 30% to 100% recoveries when liquidity and news catalysts reappear, making a defined oversold bounce strategy appropriate for nimble traders.

Fundamentals, valuation and Meyka AI grade for RSH.AX stock

Respiri reports negative earnings with EPS -0.01 and a trailing PE of -3.30, reflecting persistent losses. Key ratios include price-to-sales 113.77 and price-to-book 12.74, highlighting elevated valuation on minimal revenue. Meyka AI rates RSH.AX with a score out of 100: 67.61 (Grade B) — HOLD. This grade factors in S&P 500 and sector comparison, financial growth, key metrics, and analyst inputs. These grades are informational only and not financial advice.

RSH.AX stock technical setup and trading plan

Short-term technicals show the stock below its 50-day average A$0.041 and 200-day average A$0.053, increasing the probability of a mean-reversion bounce. Day range A$0.03–A$0.033 and average volume 870,341.00 imply thin liquidity; use limit orders and tight risk controls. A pragmatic entry is near A$0.033 with a stop under A$0.029, and an initial target at A$0.070 to capture a fast oversold rebound.

Catalysts, risks and what to watch in RSH.AX stock news

Catalysts that would sustain a bounce include product updates, stronger subscription uptake for wheezo and improved cash flow. Watch earnings announcements and cash balance updates. Key risks: continued negative operating cash flow per share -0.00653, high price-to-sales, and low trading liquidity. A failure to hold A$0.03 would risk revisit to the year low A$0.021.

RSH.AX stock forecast, price targets and scenarios

Meyka AI’s forecast model projects a 1-year median of A$0.06970, a 3-year median of A$0.08876, and a 5-year median of A$0.10748. Versus the current A$0.033, the 1-year forecast implies an upside of 111.21%, and the 3-year forecast implies 169.57% upside. Forecasts are model-based projections and not guarantees. Use these as scenario anchors for risk-reward sizing.

Final Thoughts

RSH.AX stock sits in a classical oversold position after a sharp YTD fall and low-volume trading. Short-term traders can target a technical rebound to A$0.07 while keeping stops tight given limited liquidity and weak cash flow metrics. Meyka AI’s model projects A$0.06970 in 12 months, implying roughly 111.21% upside from A$0.033, but that projection is model-based and not guaranteed. For longer-horizon investors, valuation metrics such as price-to-sales 113.77, price-to-book 12.74, and negative EPS require a clear operational improvement before upgrading position size. Monitor earnings updates, product adoption metrics and daily volume to validate any oversold bounce trade.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.